185 related articles for article (PubMed ID: 32373678)
1. Transient receptor potential vanilloid 1 and 4 double knockout leads to increased bone mass in mice.
Nishimura H; Kawasaki M; Tsukamoto M; Menuki K; Suzuki H; Matsuura T; Baba K; Motojima Y; Fujitani T; Ohnishi H; Yamanaka Y; Kosugi K; Okada Y; Tokuda K; Tajima T; Yoshioka T; Okimoto N; Ueta Y; Sakai A
Bone Rep; 2020 Jun; 12():100268. PubMed ID: 32373678
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
3. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
4. TRPV1 deletion impaired fracture healing and inhibited osteoclast and osteoblast differentiation.
He LH; Liu M; He Y; Xiao E; Zhao L; Zhang T; Yang HQ; Zhang Y
Sci Rep; 2017 Feb; 7():42385. PubMed ID: 28225019
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
6. Knockout of TRPV6 causes osteopenia in mice by increasing osteoclastic differentiation and activity.
Chen F; Ni B; Yang YO; Ye T; Chen A
Cell Physiol Biochem; 2014; 33(3):796-809. PubMed ID: 24686448
[TBL] [Abstract][Full Text] [Related]
7. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
8. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.
Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF
J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403
[TBL] [Abstract][Full Text] [Related]
9. Water extract of Rumex crispus prevents bone loss by inhibiting osteoclastogenesis and inducing osteoblast mineralization.
Shim KS; Lee B; Ma JY
BMC Complement Altern Med; 2017 Oct; 17(1):483. PubMed ID: 29070038
[TBL] [Abstract][Full Text] [Related]
10. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
11. Elcatonin prevents bone loss caused by skeletal unloading by inhibiting preosteoclast fusion through the unloading-induced high expression of calcitonin receptors in bone marrow cells.
Tsukamoto M; Menuki K; Murai T; Hatakeyama A; Takada S; Furukawa K; Sakai A
Bone; 2016 Apr; 85():70-80. PubMed ID: 26851124
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
13. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
14. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
15. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts.
Masuyama R; Vriens J; Voets T; Karashima Y; Owsianik G; Vennekens R; Lieben L; Torrekens S; Moermans K; Vanden Bosch A; Bouillon R; Nilius B; Carmeliet G
Cell Metab; 2008 Sep; 8(3):257-65. PubMed ID: 18762026
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function.
Furlan F; Galbiati C; Jorgensen NR; Jensen JE; Mrak E; Rubinacci A; Talotta F; Verde P; Blasi F
J Bone Miner Res; 2007 Sep; 22(9):1387-96. PubMed ID: 17539736
[TBL] [Abstract][Full Text] [Related]
17. Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair.
Georgy SR; Pagel CN; Ghasem-Zadeh A; Zebaze RM; Pike RN; Sims NA; Mackie EJ
Bone; 2012 Mar; 50(3):704-12. PubMed ID: 22173052
[TBL] [Abstract][Full Text] [Related]
18. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
[TBL] [Abstract][Full Text] [Related]
19. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
20. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts and regulates bone mass.
Masuyama R; Mizuno A; Komori H; Kajiya H; Uekawa A; Kitaura H; Okabe K; Ohyama K; Komori T
J Bone Miner Res; 2012 Aug; 27(8):1708-21. PubMed ID: 22492541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
